Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Clinical Pearls I
- Outcome data should support the use of any expensive test
- Data does not exist to support the routine use of MRI in DCIS patients and invasive breast cancer patients
Clinical Pearls II
- It would be beneficial to have guidelines for the appropriate use of MRI
- Currently, the use of MRI is largely dependent on the surgeon and institution
Ruxolitinib Extended-Release Could Mitigate Risk/Increase Compliance for Patients With MPNs
March 24th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Read More
2 Clarke Drive
Cranbury, NJ 08512